ARTMS has submitted a drug master file to the U.S. Food and Drug Administration (FDA) for multicurie production of the radioisotope gallium-68 using the company's technology and medical cyclotrons.
ARTMS made the move because the current supply chain for germanium and gallium generators cannot keep up with projected demand. Getting approval from the FDA will help solve supply issues by enabling the company to use its network of cyclotrons to produce the radioisotopes.
